Cite
HARVARD Citation
Morscher, R. et al. (2021). First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. European journal of cancer. pp. 268-277. [Online].